Loading…

Neutrophil Influx and Chemokine Production during the Early Phases of the Antitumor Response to the Vascular Disrupting Agent DMXAA (ASA404)1

5,6-Dimethylxanthenone-4-acetic acid (DMXAA) acts through tumor vascular disruption and cytokine production and is the first of its class to enter phase 3 trials. We characterized leukocytes and cytokines in murine Colon 38 tumors before and after DMXAA treatment. Tumor mass declined 50% 24 hours af...

Full description

Saved in:
Bibliographic Details
Published in:Neoplasia (New York, N.Y.) N.Y.), 2009-08, Vol.11 (8), p.793-803
Main Authors: Wang, Liang-Chuan S, Thomsen, Lotte, Sutherland, Rachel, Reddy, Charu B, Tijono, Sofian M, Chen, Chun-Jen J, Angel, Catherine E, Dunbar, P Rod, Ching, Lai-Ming
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 803
container_issue 8
container_start_page 793
container_title Neoplasia (New York, N.Y.)
container_volume 11
creator Wang, Liang-Chuan S
Thomsen, Lotte
Sutherland, Rachel
Reddy, Charu B
Tijono, Sofian M
Chen, Chun-Jen J
Angel, Catherine E
Dunbar, P Rod
Ching, Lai-Ming
description 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) acts through tumor vascular disruption and cytokine production and is the first of its class to enter phase 3 trials. We characterized leukocytes and cytokines in murine Colon 38 tumors before and after DMXAA treatment. Tumor mass declined 50% 24 hours after DMXAA administration, but the leukocyte count per gram of tumor increased threefold owing to a large influx of Ly6G + CD11b + F4/80 - cells with the morphology of neutrophils. However, B and T lymphocytes, natural killer cells, and macrophages in the tumor all decreased in numbers. Seven chemokines were substantially induced in the tumor, spleen, and serum 4 hours after DMXAA administration. Using cultured spleen cell subpopulations, CD11b + cells (largely monocytes and macrophages) were shown to be the primary producers of tumor necrosis factor α, interleukin 6 (IL-6), and macrophage inflammatory 1α (MIP-1α). CD49b + natural killer cells produced IP-10, whereas CD45R + B lymphocytes produced regulated upon activation normal T cell express sequence. T lymphocytes were not major producers of cytokines in the response to DMXAA. Murine peripheral blood leukocytes (PBLs) produced a similar panel of cytokines in culture to that detected in mouse serum after DMXAA treatment. Cytokines in human PBL cultures were subsequently measured with the aim of identifying potential serum markers of the human response to DMXAA. IP-10 ( P < .001), monocyte chemoattractant protein 1 ( P < .001), and sCD40L ( P < .01) were decreased, whereas IL-8 ( P < .001) and MIP-1α ( P = .03) were increased in DMXAA-treated compared with untreated PBL cultures from a group of 12 donors.
format article
fullrecord <record><control><sourceid>pubmedcentral</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2713591</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_2713591</sourcerecordid><originalsourceid>FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_27135913</originalsourceid><addsrcrecordid>eNqljMtKAzEYhYMotlXf4V_qYiBJ59LZCKGt6EIpKuIuxJnMTDSThFzEPoTvbC1uXHd1DufjfEdoSvKqzIpiUR7vekFptsCYTtAshHeMSUmq6hRNSF3mNcX1FH0_yBS9dYPScGc6nb5AmBaWgxzthzISNt62qYnKGmiTV6aHOEhYC6-3sBlEkAFst9-YiSqm0Xp4lMFZEyREuycvIjRJCw8rFXxy8dfCemkirO5fGYNL9sRynF-Rc3TSCR3kxV-eoeub9fPyNnPpbZRts7t4obnzahR-y61Q_D8xauC9_eS0IvOiJvODBT_k322w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Neutrophil Influx and Chemokine Production during the Early Phases of the Antitumor Response to the Vascular Disrupting Agent DMXAA (ASA404)1</title><source>Open Access: PubMed Central</source><source>ScienceDirect (Online service)</source><creator>Wang, Liang-Chuan S ; Thomsen, Lotte ; Sutherland, Rachel ; Reddy, Charu B ; Tijono, Sofian M ; Chen, Chun-Jen J ; Angel, Catherine E ; Dunbar, P Rod ; Ching, Lai-Ming</creator><creatorcontrib>Wang, Liang-Chuan S ; Thomsen, Lotte ; Sutherland, Rachel ; Reddy, Charu B ; Tijono, Sofian M ; Chen, Chun-Jen J ; Angel, Catherine E ; Dunbar, P Rod ; Ching, Lai-Ming</creatorcontrib><description>5,6-Dimethylxanthenone-4-acetic acid (DMXAA) acts through tumor vascular disruption and cytokine production and is the first of its class to enter phase 3 trials. We characterized leukocytes and cytokines in murine Colon 38 tumors before and after DMXAA treatment. Tumor mass declined 50% 24 hours after DMXAA administration, but the leukocyte count per gram of tumor increased threefold owing to a large influx of Ly6G + CD11b + F4/80 - cells with the morphology of neutrophils. However, B and T lymphocytes, natural killer cells, and macrophages in the tumor all decreased in numbers. Seven chemokines were substantially induced in the tumor, spleen, and serum 4 hours after DMXAA administration. Using cultured spleen cell subpopulations, CD11b + cells (largely monocytes and macrophages) were shown to be the primary producers of tumor necrosis factor α, interleukin 6 (IL-6), and macrophage inflammatory 1α (MIP-1α). CD49b + natural killer cells produced IP-10, whereas CD45R + B lymphocytes produced regulated upon activation normal T cell express sequence. T lymphocytes were not major producers of cytokines in the response to DMXAA. Murine peripheral blood leukocytes (PBLs) produced a similar panel of cytokines in culture to that detected in mouse serum after DMXAA treatment. Cytokines in human PBL cultures were subsequently measured with the aim of identifying potential serum markers of the human response to DMXAA. IP-10 ( P &lt; .001), monocyte chemoattractant protein 1 ( P &lt; .001), and sCD40L ( P &lt; .01) were decreased, whereas IL-8 ( P &lt; .001) and MIP-1α ( P = .03) were increased in DMXAA-treated compared with untreated PBL cultures from a group of 12 donors.</description><identifier>ISSN: 1522-8002</identifier><identifier>EISSN: 1476-5586</identifier><identifier>PMID: 19649209</identifier><language>eng</language><publisher>Neoplasia Press Inc</publisher><ispartof>Neoplasia (New York, N.Y.), 2009-08, Vol.11 (8), p.793-803</ispartof><rights>Copyright © 2009 Neoplasia Press, Inc. All rights reserved</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713591/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713591/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,53791,53793</link.rule.ids></links><search><creatorcontrib>Wang, Liang-Chuan S</creatorcontrib><creatorcontrib>Thomsen, Lotte</creatorcontrib><creatorcontrib>Sutherland, Rachel</creatorcontrib><creatorcontrib>Reddy, Charu B</creatorcontrib><creatorcontrib>Tijono, Sofian M</creatorcontrib><creatorcontrib>Chen, Chun-Jen J</creatorcontrib><creatorcontrib>Angel, Catherine E</creatorcontrib><creatorcontrib>Dunbar, P Rod</creatorcontrib><creatorcontrib>Ching, Lai-Ming</creatorcontrib><title>Neutrophil Influx and Chemokine Production during the Early Phases of the Antitumor Response to the Vascular Disrupting Agent DMXAA (ASA404)1</title><title>Neoplasia (New York, N.Y.)</title><description>5,6-Dimethylxanthenone-4-acetic acid (DMXAA) acts through tumor vascular disruption and cytokine production and is the first of its class to enter phase 3 trials. We characterized leukocytes and cytokines in murine Colon 38 tumors before and after DMXAA treatment. Tumor mass declined 50% 24 hours after DMXAA administration, but the leukocyte count per gram of tumor increased threefold owing to a large influx of Ly6G + CD11b + F4/80 - cells with the morphology of neutrophils. However, B and T lymphocytes, natural killer cells, and macrophages in the tumor all decreased in numbers. Seven chemokines were substantially induced in the tumor, spleen, and serum 4 hours after DMXAA administration. Using cultured spleen cell subpopulations, CD11b + cells (largely monocytes and macrophages) were shown to be the primary producers of tumor necrosis factor α, interleukin 6 (IL-6), and macrophage inflammatory 1α (MIP-1α). CD49b + natural killer cells produced IP-10, whereas CD45R + B lymphocytes produced regulated upon activation normal T cell express sequence. T lymphocytes were not major producers of cytokines in the response to DMXAA. Murine peripheral blood leukocytes (PBLs) produced a similar panel of cytokines in culture to that detected in mouse serum after DMXAA treatment. Cytokines in human PBL cultures were subsequently measured with the aim of identifying potential serum markers of the human response to DMXAA. IP-10 ( P &lt; .001), monocyte chemoattractant protein 1 ( P &lt; .001), and sCD40L ( P &lt; .01) were decreased, whereas IL-8 ( P &lt; .001) and MIP-1α ( P = .03) were increased in DMXAA-treated compared with untreated PBL cultures from a group of 12 donors.</description><issn>1522-8002</issn><issn>1476-5586</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqljMtKAzEYhYMotlXf4V_qYiBJ59LZCKGt6EIpKuIuxJnMTDSThFzEPoTvbC1uXHd1DufjfEdoSvKqzIpiUR7vekFptsCYTtAshHeMSUmq6hRNSF3mNcX1FH0_yBS9dYPScGc6nb5AmBaWgxzthzISNt62qYnKGmiTV6aHOEhYC6-3sBlEkAFst9-YiSqm0Xp4lMFZEyREuycvIjRJCw8rFXxy8dfCemkirO5fGYNL9sRynF-Rc3TSCR3kxV-eoeub9fPyNnPpbZRts7t4obnzahR-y61Q_D8xauC9_eS0IvOiJvODBT_k322w</recordid><startdate>20090801</startdate><enddate>20090801</enddate><creator>Wang, Liang-Chuan S</creator><creator>Thomsen, Lotte</creator><creator>Sutherland, Rachel</creator><creator>Reddy, Charu B</creator><creator>Tijono, Sofian M</creator><creator>Chen, Chun-Jen J</creator><creator>Angel, Catherine E</creator><creator>Dunbar, P Rod</creator><creator>Ching, Lai-Ming</creator><general>Neoplasia Press Inc</general><scope>5PM</scope></search><sort><creationdate>20090801</creationdate><title>Neutrophil Influx and Chemokine Production during the Early Phases of the Antitumor Response to the Vascular Disrupting Agent DMXAA (ASA404)1</title><author>Wang, Liang-Chuan S ; Thomsen, Lotte ; Sutherland, Rachel ; Reddy, Charu B ; Tijono, Sofian M ; Chen, Chun-Jen J ; Angel, Catherine E ; Dunbar, P Rod ; Ching, Lai-Ming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_27135913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Liang-Chuan S</creatorcontrib><creatorcontrib>Thomsen, Lotte</creatorcontrib><creatorcontrib>Sutherland, Rachel</creatorcontrib><creatorcontrib>Reddy, Charu B</creatorcontrib><creatorcontrib>Tijono, Sofian M</creatorcontrib><creatorcontrib>Chen, Chun-Jen J</creatorcontrib><creatorcontrib>Angel, Catherine E</creatorcontrib><creatorcontrib>Dunbar, P Rod</creatorcontrib><creatorcontrib>Ching, Lai-Ming</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neoplasia (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Liang-Chuan S</au><au>Thomsen, Lotte</au><au>Sutherland, Rachel</au><au>Reddy, Charu B</au><au>Tijono, Sofian M</au><au>Chen, Chun-Jen J</au><au>Angel, Catherine E</au><au>Dunbar, P Rod</au><au>Ching, Lai-Ming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neutrophil Influx and Chemokine Production during the Early Phases of the Antitumor Response to the Vascular Disrupting Agent DMXAA (ASA404)1</atitle><jtitle>Neoplasia (New York, N.Y.)</jtitle><date>2009-08-01</date><risdate>2009</risdate><volume>11</volume><issue>8</issue><spage>793</spage><epage>803</epage><pages>793-803</pages><issn>1522-8002</issn><eissn>1476-5586</eissn><abstract>5,6-Dimethylxanthenone-4-acetic acid (DMXAA) acts through tumor vascular disruption and cytokine production and is the first of its class to enter phase 3 trials. We characterized leukocytes and cytokines in murine Colon 38 tumors before and after DMXAA treatment. Tumor mass declined 50% 24 hours after DMXAA administration, but the leukocyte count per gram of tumor increased threefold owing to a large influx of Ly6G + CD11b + F4/80 - cells with the morphology of neutrophils. However, B and T lymphocytes, natural killer cells, and macrophages in the tumor all decreased in numbers. Seven chemokines were substantially induced in the tumor, spleen, and serum 4 hours after DMXAA administration. Using cultured spleen cell subpopulations, CD11b + cells (largely monocytes and macrophages) were shown to be the primary producers of tumor necrosis factor α, interleukin 6 (IL-6), and macrophage inflammatory 1α (MIP-1α). CD49b + natural killer cells produced IP-10, whereas CD45R + B lymphocytes produced regulated upon activation normal T cell express sequence. T lymphocytes were not major producers of cytokines in the response to DMXAA. Murine peripheral blood leukocytes (PBLs) produced a similar panel of cytokines in culture to that detected in mouse serum after DMXAA treatment. Cytokines in human PBL cultures were subsequently measured with the aim of identifying potential serum markers of the human response to DMXAA. IP-10 ( P &lt; .001), monocyte chemoattractant protein 1 ( P &lt; .001), and sCD40L ( P &lt; .01) were decreased, whereas IL-8 ( P &lt; .001) and MIP-1α ( P = .03) were increased in DMXAA-treated compared with untreated PBL cultures from a group of 12 donors.</abstract><pub>Neoplasia Press Inc</pub><pmid>19649209</pmid></addata></record>
fulltext fulltext
identifier ISSN: 1522-8002
ispartof Neoplasia (New York, N.Y.), 2009-08, Vol.11 (8), p.793-803
issn 1522-8002
1476-5586
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2713591
source Open Access: PubMed Central; ScienceDirect (Online service)
title Neutrophil Influx and Chemokine Production during the Early Phases of the Antitumor Response to the Vascular Disrupting Agent DMXAA (ASA404)1
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T14%3A30%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neutrophil%20Influx%20and%20Chemokine%20Production%20during%20the%20Early%20Phases%20of%20the%20Antitumor%20Response%20to%20the%20Vascular%20Disrupting%20Agent%20DMXAA%20(ASA404)1&rft.jtitle=Neoplasia%20(New%20York,%20N.Y.)&rft.au=Wang,%20Liang-Chuan%20S&rft.date=2009-08-01&rft.volume=11&rft.issue=8&rft.spage=793&rft.epage=803&rft.pages=793-803&rft.issn=1522-8002&rft.eissn=1476-5586&rft_id=info:doi/&rft_dat=%3Cpubmedcentral%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_2713591%3C/pubmedcentral%3E%3Cgrp_id%3Ecdi_FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_27135913%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/19649209&rfr_iscdi=true